Literature DB >> 2297569

Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.

I R Peake1, M B Liddell, P Moodie, G Standen, D J Mancuso, E A Tuley, L A Westfield, J M Sorace, J E Sadler, C L Verweij.   

Abstract

Southern blotting was performed with cDNA probes for the human von Willebrand factor (vWF) gene on six patients with severe type III von Willebrand's disease (vWD). A partial deletion in the 3' end of the vWF gene was demonstrated in one individual whose parents were related and who had an alloantibody inhibitor to vWF. A resulting novel 2.0-kilobase (kb) EcoRI fragment was used for carrier detection within the patient's family, and seven carriers of this recessive trait were identified. Of the six tested, five had normal or only slightly reduced levels of vWF antigen, but with generally higher levels of factor VIII. The sixth carrier had moderately severe vWD and it is proposed that this patient is heterozygous for the defective vWF gene and a second recessive vWF defect. The novel 2.0-kb EcoRI restriction fragment was cloned and sequenced, and compared with that of the corresponding normal 4.2-kb EcoRI fragment that includes exons 41 and 42 of the vWF gene. A deletion of 2,320 base pairs (bp) which included exon 42, was identified and a novel 182-bp insert was found between the breakpoints. This insert was detected by polymerase chain reaction amplification both in the patient's DNA and in his carrier relatives.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297569

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Barriers to the development of collaborative research in general practice: a qualitative study.

Authors:  R W Gray; N J Woodward; Y H Carter
Journal:  Br J Gen Pract       Date:  2001-03       Impact factor: 5.386

2.  Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; D Lillicrap
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

3.  Polymerase chain reaction amplification of two polymorphic simple repeat sequences within the von Willebrand factor gene: application to family studies in von Willebrand disease.

Authors:  A M Cumming; J G Armstrong; K Pendry; A M Burn; R T Wensley
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

4.  In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion.

Authors:  A Cartwright; I R Peake; A C Goodeve; D J Hampshire
Journal:  Haemophilia       Date:  2016-08-01       Impact factor: 4.287

5.  Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis.

Authors:  W C Nichols; S E Lyons; J S Harrison; R L Cody; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

6.  The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.

Authors:  K A Cooney; W C Nichols; M E Bruck; W F Bahou; A D Shapiro; E J Bowie; H R Gralnick; D Ginsburg
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

7.  Genetic and blood coagulation characterization of "Swedish" families with von Willebrand's disease types I and III: new aspects of heredity.

Authors:  M Anvret; M Blombäck; M Lindstedt; E Söderlind; M Tapper-Persson; A C Thelander
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

8.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

9.  Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta.

Authors:  G R Standen; F J Steers; L Jones
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

10.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.